SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2000
EMISPHERE TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-10615 13-3306985
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File No.) Identification No.)
incorporation)
765 Old Saw Mill River Road, Tarrytown, New York 10591
------------------------------------------------ -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (914) 347-2220
<PAGE>
Item 5. Other Events.
-------------
Emisphere Technologies, Inc. ("Emisphere" or the "Company") announced
today that it is initiating clinical testing of a solid oral dosage form of
heparin. The study is a Phase I safety and tolerability study in healthy
subjects and is being conducted in the United Kingdom. In animal models leading
to the commencement of this study, Emisphere has demonstrated that its solid
dosage form of heparin does not require heparin amounts greater than what is
contained in the Company's liquid dosage form, currently in Phase III
development, to achieve a comparable therapeutic response and bioavailability to
the liquid dosage form.
<PAGE>
Signatures
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: March 16, 2000
EMISPHERE TECHNOLOGIES, INC.
/s/ Charles H. Abdalian
-----------------------
Name: Chalres H. Abdalian, Jr.
Title: Vice President, Chief Finaicial
Officer and Secretary
